Protagonist Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDProtagonist Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 84), indicating clear outperformance against the broad market. Earnings growth of 126% provides fundamental context to the price action. Investors should exercise caution due to high volatility (51% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $103.19 | +9.37% | ABOVE |
| 50 SMA | $102.31 | +10.32% | ABOVE |
| 100 SMA | $97.05 | +16.29% | ABOVE |
| 150 SMA | $93.48 | +20.73% | ABOVE |
| 200 SMA | $87.50 | +28.98% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is PTGX in an uptrend right now?
PTGX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, PTGX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is PTGX overbought or oversold?
PTGX's RSI (14) is 62. The stock is in neutral territory, neither overbought nor oversold.
Is PTGX outperforming the market?
PTGX has a Relative Strength (RS) Rating of 84 out of 99. Yes, PTGX is a market leader, outperforming 84% of all stocks over the past 12 months.
Where is PTGX in its 52-week range?
PTGX is trading at $112.86, which is 99% of its 52-week high ($114.48) and 98% above its 52-week low ($49.38).
How volatile is PTGX?
PTGX has a Beta of 0.29 and 52-week volatility of 51%. It's less volatile than the S&P 500 - generally more stable.